Linezolid-Associated Thrombocytopenia: Assessment of Risk Factors in Patients without Hemato-Oncologic Diseases

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(8), P. 2380 - 2380

Published: April 19, 2024

Background: Linezolid is used for Gram-positive bacterial infections. Thrombocytopenia one of its main adverse effects resulting from myelosuppression. Several studies have assessed risk factors that may increase the this effect. However, most included patients with hemato-oncologic diseases, which confound such assessments. This study aimed to investigate linezolid-associated thrombocytopenia in without diseases. Methods: was a multicenter retrospective case-control adult treated linezolid twice daily ≥3 days. Patients active dengue fever, COVID-19, baseline platelet count <100 × 103/mm3, concurrent therapy trimethoprim/sulfamethoxazole or valproic acid, and recent transfusion within 7 days were excluded. defined as drop below 100 103/mm3. Results: Out 158 evaluated patients, 33 developed thrombocytopenia, indicating an incidence rate 20.9%. Of all assessed, creatinine clearance <60 mL/min bacteremia/infective endocarditis significantly associated (adjusted odds ratios, 3.25 5.95; 95% CI 1.12–9.45 1.23–28.66; p = 0.031 0.026, respectively). End counts lower cases than controls (79 vs. 243 103/mm3; < 0.001). Similarly, percentage change different (−55.1% −10.2%; Conclusions: In our study, 20.9%, we found renal impairment bacteremia need close monitoring counts. Prospective are warranted evaluate potential dose adjustment.

Language: Английский

The Potential Impact of Artificial Intelligence-Assisted Carbon-Nanotube Field-Effect-Transistor (CNT-FET)-Based Nano-Biosensors on The Diagnosis of The Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology/Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology, Journal Year: 2024, Volume and Issue: 16(2), P. 47 - 61

Published: July 22, 2024

Rapid, appropriate, and reliable diagnosis is paramount for selecting a suitable therapeutic intervention the clinical management of COVID-19. Several serological molecular diagnostic methods are available, however, biosensor-based has been employed in viral diseases including COVID-19 due to its high specificity, sensitivity, expeditiousness, low cost, capability detect analyte even at concentrations, especially during initial stage infection pathogenesis. Due conductivity, thermal mechanical stability CNT, it considered potential candidate biosensor development, instance, CNT-FET-based biosensors. However, designing simulating high-performance, low-power, miniaturized CNT-FET nanoelectronic device applications, especially, point-of-care testing (POCT) crucial rapid appropriate other related diseases. Taking leverage advancement artificial intelligence, attempts have made boost technology development efficient models with accurate performance. This article explains fundamental concept disease, application intelligence increase accuracy high-performance model, approach standardize design variables performance parameters circuit diagnosis. Moreover, highlights current challenges meaningful insights into their disease beyond future perspective sensors

Language: Английский

Unveiling coagulation dysfunction in patients with COVID-19: a retrospective analysis

Journal of Medicine and Life, Journal Year: 2024, Volume and Issue: 17(9), P. 886 - 891

Published: Sept. 1, 2024

Coagulation dysfunction has emerged as a significant aspect of COVID-19 pathophysiology, with abnormal coagulation parameters observed in severe cases. This study aimed to investigate the predictive value parameters, including prothrombin time (PT), activated partial thromboplastin (PTT), and international normalized ratio (INR) for mortality patients COVID-19. A retrospective analysis was conducted on cohort diagnosed PT, PTT, INR, were measured upon admission. Receiver operating characteristic (ROC) curve performed evaluate performance these parameters. Sensitivity specificity calculated, area under (AUC) values determined. The included 156 t-test revealed difference (P < 0.05) INR. PTT demonstrated highest performance, an AUC 0.68, indicating superior discrimination compared PT exhibited sensitivity 83% 46% identifying deceased patients. These findings suggest that may serve valuable prognostic marker risk indicators, particularly predicted mortality. Monitoring markers help stratify guide treatment. Further research validation studies are needed corroborate establish clinical importance therapy. mechanisms must be understood order design targeted therapies reduce thrombotic consequences.

Language: Английский